X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
POLB 001 is a novel small molecule, orally administered p38 MAP kinase inhibitor. It is being evaluated under in-vivo studies for the treatment of cytokine release syndrome.
Lead Product(s): POLB001
Therapeutic Area: Immunology Product Name: POLB001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
Under the collaboration, the Company will produce a prototype drug utilising Poolbeg's licensed oral delivery technology. Poolbeg believes that this technology can help to optimise the delivery of its partner's novel drug to its ideal site of therapeutic action.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 17, 2023
Details:
POLB 001 reduces hyperinflammation which is associated with CRS, has the potential to significantly reduce the serious adverse effects experienced by many CAR T cell patients.
Lead Product(s): POLB 001
Therapeutic Area: Oncology Product Name: POLB 001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
POLB 001 is a unique potential treatment for viruses such as severe influenza as it is strain agnostic, unlike other flu treatments and prophylactics. This means that it can be effective regardless of which strain of influenza is dominant in any particular season or geography.
Lead Product(s): POLB 001
Therapeutic Area: Infections and Infectious Diseases Product Name: POLB 001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
POLB 001 is a small molecule immunomodulator for the treatment of severe influenza. POLB 001 electively inhibits overwhelming inflammation in viral infections, such as influenza, while leaving the necessary immune functions intact to fight the infection.
Lead Product(s): POLB 001
Therapeutic Area: Infections and Infectious Diseases Product Name: POLB 001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
